Did you know? You can suggest edits to improve this peptide information.
Overview
What is Cerebrolysin?
Cerebrolysin is a standardized neuropeptide preparation derived from purified porcine brain proteins, containing bioactive peptides and amino acids that exhibit neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement.
Key Benefits
Direct brain delivery, standardized dosing, extensive clinical evidence, ready-to-use formulation
Mechanism of Action
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors
Pharmacokinetics
Research Indications
Alzheimer's Disease - Mixed Evidence
Meta-analyses show modest cognitive improvements, though clinical significance remains debated in medical literature
Vascular Dementia - Established Efficacy
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements with well-documented protocols
Post-Stroke Cognitive Recovery
Large meta-analysis shows significant NIHSS improvements, though other studies found no functional benefit
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Start as soon as possible for acute conditions (stroke/TBI). Chronic conditions use 5-day weekly schedules. Administer in morning when possible.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Break ampoule and extract Cerebrolysin contents immediately before use
For direct injection: Up to 10 mL IV undiluted (slow over 3 minutes) or up to 5 mL IM undiluted
For infusion: Dilute 10-50 mL Cerebrolysin to minimum 100 mL total volume with compatible solution
Start infusion immediately after dilution - infuse within 15 minutes
Flush IV catheter with sodium chloride solution before and after administration
Use disposable one-way infusion sets - discard after use to guarantee sterility
Quality Indicators
Clear amber solution from reputable source
Cerebrolysin should be clear amber colored without particles. Ensure sourcing from authorized EVER Pharma distributors
Room temperature storage ≤25°C as specified
Store at room temperature per official prescribing information, never freeze
Protected from light
Stored in original carton to protect from light exposure
Clinical evidence awareness
Be aware that research shows mixed results - some large studies positive, others neutral
Research quality considerations
Some published studies have been retracted due to research misconduct - rely on independent meta-analyses
Frozen product or improper storage
Never freeze Cerebrolysin - freezing damages peptide structure and renders product ineffective
Mixing with incompatible solutions
Do not mix with amino acid solutions, vitamins, or cardiovascular medications per official guidelines
What to Expect
- Week 1-2: Initial neuroprotective effects, possible mild side effects (dizziness, agitation)
- Week 2-4: Neurological improvements become apparent, cognitive function may begin to improve
- Week 4-8: Continued recovery, motor function improvements in stroke/TBI patients
- Week 8-12: Sustained benefits, cognitive enhancement plateaus in chronic conditions
Side Effects & Safety
- Monitor for allergic reactions during first administration - generally well tolerated
- Contraindicated in epilepsy and severe renal insufficiency per official prescribing information
- Clinical evidence shows mixed results - some large studies positive, others neutral
- Research integrity concerns have been raised about some published studies
- Not approved in USA but used clinically in over 50 countries worldwide
- Use disposable one-way infusion sets to guarantee sterility
References
TBI Systematic Review - Positive Outcomes (2023)
Analysis of 8,749 TBI patients across 10 studies confirms statistically significant improvements in neurological scores
View Study (opens in new tab) →CAPTAIN II Trial - Traumatic Brain Injury (2020)
Randomized controlled trial demonstrating efficacy and safety in moderate-severe TBI with improved GCS and GOS scores
View Study (opens in new tab) →Subarachnoid Hemorrhage Pilot Trial (2020)
First randomized trial in SAH patients showing promising results with 76% vs 48% favorable outcomes
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia